Press Releases - 2021-03-31

Date	Title	Company
31-Mar-2021	Americans Left in Limbo Over Lower Drug Costs	Newswire
31-Mar-2021	Seegnal’s Drug Interaction Prevention Platform 20-fold More Accurate than Standard Tech	Seegnal
31-Mar-2021	Panthera is running a Ph 3 trial for AstraZeneca’s monoclonal antibody combination to reduce the effects of COVID-19 in patients with the virus from its North Manchester site	Panthera Biopartners
31-Mar-2021	Abivax reports 2020 financial results and operations update (news with additional features)	ABIVAX
31-Mar-2021	Annual General Meeting – shareholders approve all motions of the Board of Directors	COLTENE Holding AG
31-Mar-2021	Pfizer-BioNTech Announce Positive Topline Results of Pivotal COVID-19 Vaccine Study in Adolescents	BioNTech
31-Mar-2021	Specialist pharma Amzell B.V. signs agreement with Amring Pharmaceuticals Inc.to develop and commercialize clinical-stage candidate	Amzell B.V
31-Mar-2021	Strong support for health and care reforms but clarity needed on ministerial involvement in NHS	NHS Confederation
31-Mar-2021	Sanofi to build new facility in Canada to increase global availability of high-dose influenza vaccine	Sanofi
31-Mar-2021	Cardinal Health Partners with FourKites to Build Cognitive Supply Chain	FourKites
31-Mar-2021	VMS BioMarketing Names Tom Fagan as Chief Operating Officer	Newswire
31-Mar-2021	Nanoform and Nacuity Pharmaceuticals Sign Technology Proof of Concept (“PoC”) Agreement for Two Ophthalmic Drug Candidates	Nanoform Finland Plc
31-Mar-2021	Five New 'Key Opinion Leaders' Appointed to Blinkcns Scientific Advisory Board	Newswire
31-Mar-2021	Global Cell and Gene Therapy Market	Prophecy Market Insights
31-Mar-2021	Global Oncology Biosimilar Treatment Market is estimated to be US$ 44439.4 million by 2030 with a CAGR of 57.6% during the forecast period	Prophecy Market Insights
31-Mar-2021	Global Cell and Gene Therapy Market worth US$ 1.8 billion 2019 with a CAGR of 35.60%	Prophecy Market Insights
31-Mar-2021	Celltrion Healthcare receives positive CHMP opinion for subcutaneous formulation of infliximab, Remsima® SC, for direct use of subcutaneous therapy without IV loading in adults with rheumatoid arthritis	Celltrion Healthcare
31-Mar-2021	National Horizons Centre expands as National Training Centre for the Advanced Therapies Skills Training Network (ATSTN)	National Horizons Centre
31-Mar-2021	Bachem announces the launch of their new website	Bachem
31-Mar-2021	New Equilibrium Bio raises $10M from RA Capital for AI-powered quantum chemistry	Newswire